Natco Pharma Q1 profit falls 57 pc to Rs 206.5 cr

Natco Pharma, an Indian pharmaceutical company, reported a significant decline in its first-quarter profit, falling 57% to Rs 206.5 crore. This drop in profit is largely attributed to reduced sales of its leading cancer drug, lenalidomide. The decline in sales led to a decrease in consolidated revenues compared to the prior year, impacting the company's overall financial performance. This profit decline is a concern for investors, as it may affect the company's future growth prospects and market value.

Why it matters

Natco Pharma's profit decline is due to reduced sales of its leading cancer drug. This could lead to a decrease in investor sentiment and a potential decline in the company's stock price.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Economic Times. For information only — not financial advice.